Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia

The Ohio State University

Status and phase

Completed

Phase 2

Conditions

B-Chronic Lymphocytic Leukemia

Treatments

Drug: Rituximab

Drug: Cyclophosphamide

Drug: Pentostatin

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00201721

OSU-0143

Details and patient eligibility

About

This study aims to assess the rate of complete and overall response using rituximab and pentostatin with and without cyclophosphamide, to monitor and assess toxicity of this regimen, and to determine the overall and progression-free survival in CLL patients

Full description

Rationale: Research indicates that both cyclophosphamide and pentostatin work synergistically against cancer cells and have a high response rate against chronic lymphocytic leukemia (CLL) without creating severe side effects in patients. In addition, studies have shown that rituximab, a therapy that targets the immune system, has the highest efficacy against CLL and the lowest toxicity rate when compared with other immunotherapy drugs. Studies also show that rituximab enhances the efficacy of the chemotherapy agents cyclophosphamide and pentostatin. This study offers the combination of immunotherapy with two promising chemotherapy agents against CLL.

Purpose: This study is evaluating the efficacy and safety of combination treatment with cyclophosphamide, pentostatin, and rituximab in patients with CLL. Several tests evaluating the genetic and molecular components of CLL will also be performed. Some of these tests will be conducted before, during, and after treatments to assess changes resulting from the study drugs. Each patient's outcome will be assessed in relation to various aspects of their genes.

Enrollment

28 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of B-CLL (no mantle cell)
Must have active disease
Age >=18 yo
ECOG 0-3
No radiation or surgery <4 weeks

Exclusion criteria

Any of the following comorbid conditions:
- New York Heart Association Class III or IV heart disease
- Recent myocardial infarction (<1 month)
- Uncontrolled infection
- Active infection with the human immunodeficiency virus (HIV/AIDS) as further severe immunosuppression with this regimen may occur.
Pregnant or nursing women
Men or women of child bearing potential must use adequate contraception.
Active primary malignancy requiring treatment or limits survival to ≤2 years.
Any radiation therapy ≤4 weeks prior to study entry.
Any major surgery ≤4 weeks prior to study entry.